This clinical trial focuses on treating advanced renal cell carcinoma (a type of kidney cancer) that has clear cell features and has gotten worse after previous treatment. The study tests two different treatment approaches. The first approach combines two medications: belzutifan and lenvatinib. The second approach uses a single medication called cabozantinib. These medications are taken by mouth in the form of tablets or capsules.
The purpose of this study is to compare how well these two treatment approaches work in people whose cancer has progressed after receiving a specific type of immunotherapy (anti-PD-1/L1 therapy). The study will measure which treatment is better at stopping the cancer from growing and helping patients live longer.
During the study, participants will be randomly assigned to receive either the combination of belzutifan and lenvatinib or cabozantinib alone. The treatment will continue for up to 46 months, as long as it is working and the side effects are manageable. Throughout the study, doctors will regularly check the participants’ health and monitor how their cancer responds to the treatment.
Austria 
Belgium 
Czechia 
Finland 
France 
Germany 
Greece 
Ireland 
Italy 
Poland 
Romania 
Spain 
The Netherlands 